These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36921980)

  • 1. Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA).
    Dougados M; Lucas J; Desfleurs E; Claudepierre P; Goupille P; Ruyssen-Witrand A; Saraux A; Tournadre A; Wendling D; Lukas C
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36921980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study.
    Dougados M; Lardy-Cléaud A; Desfleurs E; Claudepierre P; Goupille P; Ryussen-Witrand A; Saraux A; Tournadre A; Wendling D; Lukas C
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38428974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis.
    Armağan B; Kılıç L; Farisoğulları B; Yardımcı GK; Bilgin E; Bölek EÇ; Karadağ Ö; Bilgen ŞA; Kiraz S; Ertenli İ; Kalyoncu U
    Rheumatol Int; 2023 Jan; 43(1):147-156. PubMed ID: 36129541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.
    Min HK; Kim HR; Lee SH; Hong YS; Kim MY; Park SH; Kang KY
    Rheumatology (Oxford); 2021 Dec; 60(12):5743-5752. PubMed ID: 33725088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
    Glintborg B; Lindström U; Giuseppe DD; Provan SA; Gudbjornsson B; Hetland ML; Michelsen B; Wallman JK; Aaltonen K; Hokkanen AM; Nordström D; Jørgensen TS; Hansen RL; Geirsson AJ; Grøn KL; Krogh NS; Askling J; Kristensen LE; Jacobsson LTH;
    Arthritis Care Res (Hoboken); 2022 May; 74(5):748-758. PubMed ID: 33253491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
    Lindström U; Bengtsson K; Olofsson T; Di Giuseppe D; Glintborg B; Forsblad-d'Elia H; Jacobsson LTH; Askling J
    Ann Rheum Dis; 2021 Nov; 80(11):1445-1452. PubMed ID: 34130984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of alternative TNF inhibitor and secukinumab between primary non-responder and secondary non-responder of prior TNF inhibitor in ankylosing spondylitis.
    Min HK; Kim HR; Lee SH; Hong YS; Kim MY; Park SH; Kang KY
    Mod Rheumatol; 2023 Jan; 33(1):194-201. PubMed ID: 35107167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor efficacy of TNF inhibitors in non-radiographic axial spondyloarthritis in the absence of objective signs: A bicentric retrospective study.
    Vidal C; Lukas C; Combe B; Berenbaum F; Pers YM; Jorgensen C; Sellam J; Morel J
    Joint Bone Spine; 2018 Jul; 85(4):461-468. PubMed ID: 28917996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
    Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
    Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
    Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
    Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network.
    Inman RD; Choquette D; Khraishi M; Gladman DD; Hussein S; Neish D; Leclerc P
    J Rheumatol; 2023 May; 50(5):634-640. PubMed ID: 36642434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.
    Derakhshan MH; Dean L; Jones GT; Siebert S; Gaffney K
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32641447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis.
    Bekele DI; Cheng E; Reimold A; Geier C; Ganuthula K; Walsh JA; Clegg DO; Dubreuil M; Kaushik P; Ng B; Chang E; Duong R; Park J; Kerr GS
    Rheumatol Int; 2022 Nov; 42(11):1925-1937. PubMed ID: 34724089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
    Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
    Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Survival, Effectiveness and Safety of Secukinumab in Axial Spondyloarthritis up to 4 Years: A Real-Life Single Center Experience.
    Diaconu AD; Pomîrleanu C; Russu M; Strugariu G; Ancuța E; Ciortescu I; Bologa C; Morărașu BC; Constantin M; Ceasovschih A; Șorodoc V; Șorodoc L; Ancuța C
    J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
    Ciurea A; Götschi A; Bräm R; Bürki K; Exer P; Andor M; Nissen MJ; Möller B; Hügle T; Rubbert-Roth A; Kyburz D; Distler O; Scherer A; Micheroli R
    RMD Open; 2023 Dec; 9(4):. PubMed ID: 38053462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.